

**TSG101 Antibody (C-term)**  
**Purified Rabbit Polyclonal Antibody (Pab)**  
**Catalog # AP2155b**

## Specification

---

### TSG101 Antibody (C-term) - Product Information

Application	WB,E
Primary Accession	<a href="#">O99816</a>
Other Accession	<a href="#">O6IRE4</a> , <a href="#">O61187</a> , <a href="#">NP_006283</a>
Reactivity	Human
Predicted	Mouse, Rat
Host	Rabbit
Clonality	Polyclonal
Isotype	Rabbit IgG
Calculated MW	43944
Antigen Region	340-370

### TSG101 Antibody (C-term) - Additional Information

**Gene ID** 7251

#### Other Names

Tumor susceptibility gene 101 protein, ESCRT-I complex subunit TSG101, TSG101

#### Target/Specificity

This TSG101 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 340-370 amino acids from the C-terminal region of human TSG101.

#### Dilution

WB~~1:1000

#### Format

Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.

#### Storage

Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

#### Precautions

TSG101 Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures.

### TSG101 Antibody (C-term) - Protein Information

**Name** TSG101

**Function** Component of the ESCRT-I complex, a regulator of vesicular trafficking process. Binds to

ubiquitinated cargo proteins and is required for the sorting of endocytic ubiquitinated cargos into multivesicular bodies (MVBs). Mediates the association between the ESCRT-0 and ESCRT-I complex. Required for completion of cytokinesis; the function requires CEP55. May be involved in cell growth and differentiation. Acts as a negative growth regulator. Involved in the budding of many viruses through an interaction with viral proteins that contain a late-budding motif P-[ST]-A-P. This interaction is essential for viral particle budding of numerous retroviruses. Required for the exosomal release of SDCBP, CD63 and syndecan (PubMed:[22660413](#)). It may also play a role in the extracellular release of microvesicles that differ from the exosomes (PubMed:[22315426](#)).

#### Cellular Location

Cytoplasm. Early endosome membrane; Peripheral membrane protein; Cytoplasmic side. Late endosome membrane; Peripheral membrane protein. Cytoplasm, cytoskeleton, microtubule organizing center, centrosome. Midbody, Midbody ring. Nucleus. Note=Mainly cytoplasmic. Membrane-associated when active and soluble when inactive. Nuclear localization is cell cycle-dependent. Interaction with CEP55 is required for localization to the midbody during cytokinesis

#### Tissue Location


Heart, brain, placenta, lung, liver, skeletal, kidney and pancreas

#### TSG101 Antibody (C-term) - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

#### TSG101 Antibody (C-term) - Images



The anti-TSG101 Pab (Cat. #AP2155b) is used in Western blot to detect TSG101 in ZR75-1 cell lysate

**TSG101 Antibody (C-term) - Background**

TSG101 belongs to a group of apparently inactive homologs of ubiquitin-conjugating enzymes. The gene product contains a coiled-coil domain that interacts with stathmin, a cytosolic phosphoprotein implicated in tumorigenesis. The protein may play a role in cell growth and differentiation and act as a negative growth regulator. In vitro steady-state expression of this tumor susceptibility gene appears to be important for maintenance of genomic stability and cell cycle regulation. Mutations and alternative splicing in this gene occur in high frequency in breast cancer and suggest that defects occur during breast cancer tumorigenesis and/or progression.

**TSG101 Antibody (C-term) - References**

- Favre, M., et al., *J. Acquir. Immune Defic. Syndr.* 34(2):127-133 (2003).  
Lu, Q., et al., *Proc. Natl. Acad. Sci. U.S.A.* 100(13):7626-7631 (2003).  
Goila-Gaur, R., et al., *J. Virol.* 77(11):6507-6519 (2003).  
Blanco, S., et al., *FEMS Microbiol. Lett.* 221(2):151-154 (2003).  
Martin-Serrano, J., et al., *J. Virol.* 77(8):4794-4804 (2003).